| |
Year:
1999
| Volume: 7
| Issue: 2
| Pages: 75-80
|
| |
Review Article |
| |
INTERFERONS IN THE THEPRAPY OF SOLID TUMORS
Nevenka STANOJEVIC-BAKIC, Ljiljana VUCKOVIC-DEKIC |
| |
DOI:
|
| |
Abstract: |
| |
Biotherapy of metastatic renal cell carcinoma (RCC) is the matter of great interest during the last decade, which is due to the disappointing results of conventional oncologic therapy. The introduction of interferon (INF) improved, in comparison to other approaches, the therapeutical response of RCC patients. The most efficacious was proved to be IFNalfa. This agent was used as monotherapy, but also was combined with other IFNs, other cytokines, and/or various chemotherapeutics. When used as single agent therapy, IFNalfa gave overall response (OR) of about 15-20%, while IFNgama therapy was less effective (OR below 10%). The combination of these two IFN types slightly improved the response rate (22%). When IFN was used with an other potent cytokine, interleukin-2 (IL-2), the therapeutic response varied greatly (0-45%), with average OR of 19%. Similar results were obtained when IFNalfa was combined with cytostatics, usually vinblastine, and with fluoropyrimidine analogues as well (OR 21% and 23%, respectively). Recent few multiagent combination studies using IFNalfa+I1-2+5-FU gave the bes OR reported thus far (34%). Taking as a whole, although these results are encouraging, they are limited to the minority of RCC patients. Therefore, efforts to define the criteria for better selection of patients, the optimal combination of biochemotherapeutics, and optimal regimen as well, are on-going. |
| |
Key words:
Interferon, Renal cell carcinoma; Immunotherapy |
| |
Read
full text in PDF [Full
Text] |
|
|